8-K current report · filed Nov 4, 2026

Harmony Biosciences Holdings, Inc. (HRMY) 8-K Current Report: November 4, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2HRMY overview

Short answer

Harmony Biosciences Holdings, Inc. (HRMY) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results announced for quarter ended September 30, 2026.

Harmony Biosciences Holdings, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Press release contains the detailed operating results and financial metrics in Exhibit 99.1
  • Results announcement provides investors the latest quarterly performance update for Harmony Biosciences

Item 7.01 · Regulation FD Disclosure

  • Investor presentation posted November 4, 2026, providing updated materials for investor and analyst discussions
  • Exhibit 99.2 contains the substantive company messaging and should be reviewed for pipeline, financial outlook, and strategic updates
  • Reg FD disclosure signals broader dissemination of management’s investor-facing information beyond selected meetings

Item EX-99.1 · Exhibit EX-99.1

  • Q3 WAKIX net revenue $268.9M, up 12% YoY, with 400 net patient adds to 9,350
  • Full-year WAKIX guidance reiterated at $1.0B to $1.04B, supporting near-term commercial visibility
  • Net income $48.2M, or $0.81 diluted EPS, pressured by higher royalties and milestone charges
  • BP-205 repeat-dose study showed no serious or severe adverse events, with Phase 1b data expected Q1 2027
  • Peter Anastasiou succeeds Jeffrey Dayno as CEO January 1, 2027, while WAKIX exclusivity is targeted through March 2030

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 WAKIX revenue $268.9M, up 12% year over year, with 400 net patient adds and 9,350 average patients
  • 2026 WAKIX revenue guidance reaffirmed at $1.00B-$1.04B, supporting continued commercial momentum
  • BP-205 Phase 1 MAD data showed generally good tolerability, ~29-hour half-life and no serious or severe treatment-emergent adverse events
  • BP-205 Phase 1b data expected Q1 2027, with multiple Phase 2 studies targeted by mid-2027
  • Cash, equivalents and investments reached $1.05B, enabling BP-205 investment and potential business-development transactions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Harmony Biosciences Holdings, Inc. 8-K filings

Get the next HRMY 8-K as it lands

Follow HRMY for push alerts, or ask the research agent what this filing means.